38P - Angiogenic factors and laminin expression in cervical cancer: correlation with treatment response

Date 20 November 2015
Event ESMO Symposium on Immuno-Oncology 2015
Session Welcome reception and general Poster viewing
Topics Cervical Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Manoj Sharma
Citation Annals of Oncology (2015) 26 (suppl_8): 5-14. 10.1093/annonc/mdv514
Authors M. Sharma1, R. Khan2, A. Sharma3, M. Aggarwal4, A. Sharma2
  • 1Department Of Radiation Oncology, Maulana Azad Medical College New Delhi A.L.N. Hospital, 110002 - New Delhi/IN
  • 2Department Of Biochemistry, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 3Department Of Medicine, Jawaharlal Nehru Medical College, Aligarh, Uttar Pradesh, Aligarh/IN
  • 4Department Of Radiation Oncology, Maulana Azad Medical College New Delhi A.L.N. Hospital, New Delhi/IN



Carcinoma of uterine cervix accounts for most common malignancy in Indian women. Tumor growth and metastasis depends primarily on angiogenesis & its surrounding environment including extracellular matrix and growth factors. VEGF is involved in angiogenesis, tumor progression, immunosuppression & immune tolerance. In presence of VEGF, Ang-2 promotes endothelial cell proliferation & migration, facilitating remodelling of neovasculature. Laminins are important for proliferation, migration & angiogenesis. Currently chemo-irradiation is mainstay of treatment in carcinoma cervix. Effect of chemo-irradiation on biomarkers like VEGF, Ang-2 & Laminin in patients with carcinoma cervix needs to be explored.


Circulatory and mRNA levels of VEGF, Ang-2 & Laminin in patients with stage III carcinoma cervix were compared with those of healthy women. Circulatory and mRNA levels of VEGF, Ang-2 & Laminin were measured prior to treatment, after chemotherapy & teleradiation, using high sensitivity ELISA kits and Q-PCR. Treatment response was assessed & correlated with data. Clinical response was also evaluated as per WHO criteria & was correlated with biochemical markers. Data was analyzed statistically.


Levels of all the studied molecules were significantly (p < 0.001) higher in patients than in controls. After treatment, their levels were significantly (p < 0.001) declined. Out of 40 patients, 33 were complete responders and 7 were non-responders when they were clinically assessed. On comparison of before and after treatment levels of these molecules complete responders showed significant decline whereas non responders showed insignificant decrease in their levels. We have followed the responders for 3 years, out of 33, 28 patients were disease free while 5 patients showed recurrence (9-26 months).


Higher levels of angiogenic factors along with laminin indicate the role played by them in the disease progression aiding angiogenesis. It may be possible that these angiogenic factors function via the up-regulation of matrix proteins such as laminins. These markers may serve as useful tools in post treatment disease mapping which otherwise may not provide true picture with available imaging methods.

Clinical trial identification


All authors have declared no conflicts of interest.